Showing 1 - 5 results of 5 for search 'Manal F Abdelmalek', query time: 0.01s Refine Results
  1. 1
    Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.

    Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pi... by Kara Wegermann, Ricardo Henao, Anna Mae Diehl, Susan K Murphy, Manal F Abdelmalek, Cynthia A Moylan

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health recordsResearch in context

    Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of... by Ayako Suzuki, Georgia Sofia Karachaliou, Amy M. Perkins, Chad Dorn, Ruth M. Reeves, Timothy Arnold, Mustafa R. Bashir, Jimmy T. Efird, Manal F. Abdelmalek, Anna Mae Diehl

    Published 2025-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction

    Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction by Kuo Du, David S. Umbaugh, Liuyang Wang, Ji Hye Jun, Rajesh K. Dutta, Seh Hoon Oh, Niansheng Ren, Qiaojuan Zhang, Dennis C. Ko, Ana Ferreira, Jon Hill, Guannan Gao, Steven S. Pullen, Vaibhav Jain, Simon Gregory, Manal F. Abdelmalek, Anna Mae Diehl

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction

    Author Correction: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction by Kuo Du, David S. Umbaugh, Liuyang Wang, Ji Hye Jun, Rajesh K. Dutta, Seh Hoon Oh, Niansheng Ren, Qiaojuan Zhang, Dennis C. Ko, Ana Ferreira, Jon Hill, Guannan Gao, Steven S. Pullen, Vaibhav Jain, Simon Gregory, Manal F. Abdelmalek, Anna Mae Diehl

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment

    Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment by Pierre-Emmanuel Rautou, Shivani Chotkoe, Louise Biquard, Guillaume Wettstein, Denise van der Graaff, Yao Liu, Joris De Man, Christophe Casteleyn, Sofie Thys, Winnok H. De Vos, Pierre Bedossa, Michael P. Cooreman, Martine Baudin, Jean-Louis Abitbol, Philippe Huot-Marchand, Lucile Dzen, Miguel Albuquerque, Pierre Broqua, Jean-Louis Junien, Luisa Vonghia, Manal F. Abdelmalek, Wilhelmus J. Kwanten, Valérie Paradis, Sven M. Francque

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: